Gastric cancer (GC), one of the most malignant types of cancer, is the second greatest cause of cancer-associated mortality worldwide. Novel therapeutic targets for GC treatment are therefore urgently required. Carboxy-terminal domain phosphatase 1 (CTDP1) has a crucial role in the regulation of gene expression. However, to the best of our knowledge, the role of CTDP1 in GC has not previously been explored.
Introduction
Gastric cancer (GC) is one of the most prevalent types of malignant cancer, and possesses the second highest cancer-associated mortality rate worldwide (1) . Although improvements in hygiene, medical technologies and food preservation techniques have led to a marked decline in the incidence and mortality of GC over the past several decades, the 5-year relative survival rate of patients with GC remains at only 29%, even in the USA (2) . Therefore, novel therapeutic methods for surgical management and the novel therapeutic targets for GC treatment remain urgently required.
Although numerous environmental factors, including Helicobacter pylori infection and dietary habits, have significant roles in gastric carcinogenesis, the genetic and epigenetic alterations of multiple genes continue to be considered to have crucial roles in this process (3) . Following developments in molecular genetics, carboxy-terminal domain phosphatase 1 (CTDP1) has attracted increasing attention. The CTDP1 gene encodes a phosphatase, FCP1, which is able to dephosphorylate the serine residues of the carboxy-terminal domain (CTD) of the largest subunit of RNA polymerase II, a significant factor involved in gene transcription in eukaryotic cells (4) . The CTD phosphorylation level of RNA polymerase II is a crucial element in the regulation of gene expression (5) . In addition, FCP1 has phosphatase-independent functions in transcriptional regulation, including as an elongation factor and as a splicing associated factor (6) . Although the functions of CTDP1 indicate that it may have an oncogenic role, the majority of research regarding CTDP1 has focused on congenital cataracts facial dysmorphism and neuropathy syndrome, which occurs as a result of CTDP1 deficiency (7) . To the best of our knowledge, the detailed role of CTDP1 in tumor development has not previously been studied.
In the present study, the role of CTDP1 in GC cells was investigated. The expression of CTDP1 was detected in various human GC cell lines, and subsequently, lentivirus-mediated small interfering RNA (siRNA) was used to silence the CTDP1 gene in a GC cell line with high CTDP1 expression. The effects of CTDP1 deficiency on the cell proliferation, cell cycle, cell apoptosis and tumor formation ability of GC cells were then evaluated.
Carboxy-terminal domain phosphatase 1 silencing results in the inhibition of tumor formation ability in gastric cancer cells

Materials and methods
Cell culture . Human GC cell lines AGS, BGC-823, SGC-7901,  HGC-27 and MGC80-3 were purchased from the American  Type Culture Collection (Manassas, VA, USA). BGC-823,  SGC-7901, HGC-27 and MGC80-3 . The relative levels of CTDP1 mRNA expression were normalized to the internal control gene, GAPDH. The specific primers were as follows: CTDP1 forward, 5'-ATA TGG ATC CAT GCA AAA TCG AGC TCG AGA-3' and reverse, 5'-GCG GCC GCT AAT CTT CAA TTT ACC CTA ATA-3'; GAPDH forward, 5'-GAA GGT GAA GGT CGG AGT C-3' and reverse, 5'-GAA GAT GGT GAT GGG ATT TC-3'.
Lentivirus-mediated siRNA gene silencing. The CTDP1 targeting siRNA sequence was 5'-CCC AGT TGC AGA GTA AGA A-3'. The sequence of the scrambled siRNA (SCR-siRNA), which served as a negative RNA interference control, was 5'-TTC TCC GAA CGT GTC ACG T-3'. The siRNA sequences were inserted into the green fluorescent protein (GFP) expression vector pGCL-GFP (GeneChem Co., Ltd., Shanghai, China). The recombinant virus was packaged using the Lentivector Expression system (GeneChem Co., Ltd), and SGC-7901 cells were infected. Three days subsequently, GFP-positive cells were counted under a fluorescence microscope (IX71 System; Olympus Corp., Tokyo, Japan). The effect of siRNA infection on CTDP1 expression was determined by RT-qPCR analysis on the fourth day. PCR cycling conditions were initially performed for 4 min at 95˚C, followed by 40 cycles at 95˚C for 10 sec and then by 60˚C for 30 sec.
Western blotting. Cell lysates were subjected to 8% SDS-PAGE (Sangon Biotech Co., Ltd., Shanghai, China). The blots were subsequently incubated with rabbit anti-human polyclonal CTDP1 antibody (dilution, 1:2,000; catalogue no. ab137683; Abcam, Cambridge, UK) overnight at 4˚C and then with secondary antibody (donkey anti-rabbit immunoglobulin G H&L horseradish peroxidase-conjugated polyclonal antibody; dilution, 1:10,000; catalogue no. ab16284; Abcam) at room temperature for 2 h and chemiluminescent substrates (catalogue no. ab5801; Abcam) at room temperature for 30 sec. Hybridization with rabbit anti-rat polyclonal anti-GAPDH antibody (dilution, 1:2,000; catalogue no. ab9485; Abcam) was used to confirm equal protein loading.
Cell proliferation assessment. GFP-positive cells with siRNA infection were separated by fluorescence-activated cell sorting (FACS) using a FACSCalibur (BD Biosciences, Franklin Lakes, NJ, USA) according to the manufacturer's instructions. FACS-sorted cells (1.0x10 3 per well) were cultured in 96-well plates, and then observed and counted using a fluorescence microscope (IX71 System; Olympus Corp.) each day for 5 days to assess proliferative ability. 
Results
Lentivirus-delivered siRNA stably inhibits CTDP1 expression in GC cells. Although CTDP1 has a crucial role in gene transcription, studies regarding CTDP1 expression in cancer, and particularly in GC, remain rare. Therefore, the expression of CTDP1 was detected in the AGS, BGC-823, SGC-7901, HGC-27 and MGC80-3 GC cell lines using RT-qPCR. The results revealed that CTDP1 was expressed in all cell lines evaluated, and was particularly highly expressed in the AGS and SGC-7901 cell lines (Fig. 1A) . SGC-7901 cells were therefore selected for further analysis of the role of CTDP1 in GC. Lentivirus-delivered siRNA was used to attenuate CTDP1 expression in SGC-7901 cells, and the efficiency of siRNA lentivirus infection was >90%. Three days following infection, >90% of the infected SGC-7901 cells expressed GFP fluorescein. The silencing effectiveness of CTDP1-siRNA on CTDP1 expression was further evaluated by RT-qPCR and western blotting. The results indicated that CTDP1 expression was efficiently inhibited by CTDP1-siRNA infection in SGC-7901 cells ( Fig. 1B and C) . These data demonstrated that CTDP1 was highly expressed in certain GC cell lines and was able to be effectively and sustainably silenced by lentivirus-delivered CTDP1-specific siRNA.
CTDP1 inhibition decreases cell proliferation ability of SGC-7901 cells. The effects of CTDP1 inhibition on GC cell proliferation. SGC-7901 cells infected with siRNA expressed GFP fluorescein. Therefore, cells that were effectively infected with siRNA were able to be separated by flow cytometry. The separated cells were harvested and monitored for 5 days. The numbers of control cells (infected with SCR-siRNA) increased ~15-fold in 5 days, while cells infected with CTDP1-siRNA exhibited no significant proliferation, and demonstrated a decrease in cell number (Fig. 2) . This result indicated that inhibition of CTDP1 by siRNA infection significantly reduced the cell proliferation ability of SGC-7901 cells (P<0.05).
CTDP1 inhibition arrests the cell cycle in SGC-7901 cells.
In order to investigate the underlying cause of the decrease in cell proliferation in SGC-7901 cells infected with CTDP1-siRNA, the effect of CTDP1 inhibition on the cell cycle was evaluated by PI staining and flow cytometric analysis. The results indicated that cells treated with SCR-siRNA had a lower percentage at G0/G1 phase than that of those treated with CTDP1-siRNA (43.7±1.6 vs. 51.2±1.3%; P<0.01). In addition, SCR-siRNA-infected cells had 16.3±1.4% at G2/M phase, while the CTDP1-siRNA cells only had 7.5±2.4% at G2/M phase (Fig. 3) . These data suggested that CTDP1 inhibition resulted in the arrest of SGC-7901 cells at the quiescent phase.
CTDP1 inhibition promotes cell apoptosis in SGC-7901 cells.
The effects of CTDP1 inhibition on cell apoptosis in GC cells was also evaluated using Annexin V-APC staining and flow cytometric analysis. The data revealed that the downregulation of CTDP1 expression resulted in a marked increase in the percentage of apoptotic cells (Annexin V positive) in SGC-7901 cells (from 6.1±0.4 to 11.9±0.7%) ( Fig. 4 ). This result demonstrated that CTDP1 inhibition enhanced apoptosis in SGC-7901 cells.
CTDP1 inhibition decreases colony formation ability in GC cells.
The aforementioned experiments indicated that inhibition of CTDP1 induced a decrease in cell proliferation ability, cell cycle arrest and an increase in cell apoptosis in SGC-7901 cells. To further investigate the impact of CTDP1 inhibition on GC cells, differences in colony formation ability between CTDP1-siRNA-infected and SCR-siRNA-infected SGC-7901 cells were evaluated. Cells were seeded in 6-well plates at a density of 200 cells/well. Following two weeks of incubation, the SCR-siRNA infected cells exhibited 5.5-fold higher colony numbers compared with those of the CTDP1-siRNA infected cells (Fig. 5 ). This suggested that CTDP1 inhibition decreased the colony formation ability of SGC-7901 cells.
Discussion
In the present study, CTDP1 expression was detected in various GC cell lines, CTDP1 expression was stably and efficiently silenced by a specific siRNA-mediated system 
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in SGC-7901 cells, and the effects of CTDP1 inhibition on SGC-7901 cells were evaluated. It was revealed that inhibition of CTDP1 decreased cell proliferation, arrested the cell cycle at G0/G1 phase and increased cell apoptosis in SGC-7901 cells. Furthermore, the colony formation ability of SGC-7901 cells was suppressed by silencing CTDP1. These results suggested that CTDP1 silencing reduced the tumor formation ability of GC cells. The primary function of FCP1, the protein encoded by CTDP1, is dephosphorylation of the CTD of RNA polymerase II, which has a critical role in the initial synthesis of mRNA and the post-transcriptional modification of mRNA (8, 9) . The phosphorylation of CTD in the largest subunit of RNA polymerase II mediates the assemblage of regulatory factors during the initial stages of mRNA synthesis (10, 11) . FCP1 dephosphorylates the CTD of RNA polymerase II in order to recycle it and further initiate a novel round of transcription. Various phosphorylation sites and potential conformational states make CTD a transcriptional controller that is able regulate mRNA production and processing (12) .
In addition to regulating RNA polymerase II, FCP1 is also involved in the regulation of RNA polymerase I. Bierhoff et al (13) found that CK2 facilitated a novel round of transcription initiation of RNA polymerase I via the phosphorylation of FCP1. Furthermore, FCP-mediated phosphorylation is not only associated with the assembly of transcription factors, but also temporally controls the cell 
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A cycle through activation of cyclin-dependent kinases and Greatwall kinase (14, 15) .
The results of the present study revealed that CTDP1 silencing resulted in proliferation inhibition and cell cycle arrest in GC cells. This indicated that normal expression of CTDP1 may be a decisive factor in cell regulation. Overexpression or silencing of CTDP1 may inhibit its associated regulation mechanisms. Schauer et al (16) found that FCP1 misregulation, whether FCP1 overexpression or silencing, induced p53-dependent and enhanced levels of caspase-mediated apoptosis in Drosophila melanogaster. The present study also found that CTDP1 silencing induced an increase in the apoptotic rate of GC cells.
In conclusion, the results of the present study suggest that CTDP1 silencing is able to suppress cell proliferation, induce cell cycle arrest, increase cell apoptosis and inhibit colony formation in SGC-7901 cells. This finding reveals that CTDP1 has a significant role in GC development, and that CTDP1 may be a promising therapeutic target in the clinical treatment of GC.
